In a high-risk patient who has undergone multiple stent procedures, what criteria do you prioritize for initiating a PCSK9 inhibitor in the setting of PCI, and what absolute LDL-C targets are in your cross-hairs based on the ODYSSEY Outcomes Trial?

In a high-risk patient who has undergone multiple stent procedures, what criteria do you prioritize for initiating a PCSK9 inhibitor in the setting of PCI, and what absolute LDL-C targets are in your cross-hairs based on the ODYSSEY Outcomes Trial?

CLICK HERE FOR CME CREDIT

In a high-risk patient who has undergone multiple stent procedures, what criteria do you prioritize for initiating a PCSK9 inhibitor in the setting of PCI, and what absolute LDL-C targets are in your cross-hairs based on the ODYSSEY Outcomes Trial?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Interventional Cardiologist's Perspective

Presenter

Phillipe Steg, MD

Phillipe Steg, MD

Professor of Cardiology Université Paris – Diderot, Sorbonne-Paris Cité Professor, National Heart and Lung Institute Imperial College, London, UK Director, Coronary Care Unit Hôpital Bichat Paris, France